Navigation Links
Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

WALTHAM, Mass., Aug. 11, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Wedbush Securities Life Sciences Management Access Conference at the Le Parker Meridien Hotel, 119 West 56th Street in New York City. The presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in the Lorica Room, located on the second floor.  

Interleukin's management team will be available for one-on-one meetings with investors participating in the Wedbush Securities Life Sciences Management Access Conference.

The presentation will be webcast live at http://www.wsw.com/webcast/wedbush17/iliu/ where it will also be archived for 90 days. The webcast link will also be available through Interleukin's website at http://www.ilgenetics.com.

About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit http://www.ilgenetics.com.Contacts:Media:

Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz Communications

Interleukin Genetics, Inc.781-684-0770

781-398-0700interleukin@schwartzcomm.com

elurier@ilgenetics.com
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
2. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
3. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
4. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
5. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
6. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
7. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
8. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
9. Interleukin Genetics Reports Second Quarter 2009 Financial Results
10. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
11. Interleukin Genetics to Present at the 2009 BIO Business Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):